公开(公告)号：US08133692B2

公开(公告)日：2012-03-13

申请号：US11490316

申请日：2006-07-20

申请人： Richard Jove ,  Susan E. Minton ,  Carlos A. Muro-Cacho ,  Daniel Sullivan ,  Eric Bruce Haura ,  Gerold Bepler

发明人： Richard Jove ,  Susan E. Minton ,  Carlos A. Muro-Cacho ,  Daniel Sullivan ,  Eric Bruce Haura ,  Gerold Bepler

IPC分类号： G01N33/53 ,  G01N33/567 ,  G01N33/574 ,  G01N33/48 ,  G01N21/00 ,  G01N21/75 ,  G01N33/566

CPC分类号： G01N33/6872 ,  C12Q1/6886 ,  C12Q2600/106 ,  G01N33/574 ,  G01N2800/52

摘要： Methods are provided for predicting responsiveness of cancer cells to chemotherapy by measuring the level of phosphorylated Stat or the level of expression of Survivin in a cancer and comparing the level in the cancer cell to the respective level in a control. Also provided are methods of selecting a chemotherapeutic treatment for a subject diagnosed with cancer by measuring the level of phosphorylated Stat or the level of expression of Survivin in a cancer and comparing the level in the cancer cell to the respective level in a control. Kits for performing the methods are also provided. Methods for modulating Survivin-dependent apoptosis in a cancer cell are also disclosed.

摘要翻译： 提供了通过测量癌症中磷酸化Stat的水平或存活蛋白表达水平，并将癌细胞中的水平与对照中的各个水平进行比较来预测癌细胞对化疗的反应性的方法。 还提供了通过测量癌症中磷酸化Stat的水平或Survivin的表达水平，并将癌细胞中的水平与对照中的各个水平进行比较来选择被诊断为癌症的受试者的化学治疗的方法。 还提供了用于执行方法的工具包。 还公开了调节癌细胞中存活蛋白依赖性细胞凋亡的方法。

公开(公告)号：US20100004257A1

公开(公告)日：2010-01-07

申请号：US12501897

申请日：2009-07-13

申请人： Eric Bruce Haura

发明人： Eric Bruce Haura

IPC分类号： A61K31/506 ,  A61P35/00 ,  A61P35/02

CPC分类号： A61K31/506 ,  G01N33/574 ,  G01N33/57423 ,  G01N2333/71 ,  G01N2800/52

摘要： A method of predicting response to treatment with inhibitors of EGFR and SRC by screening for status of key biomarkers such as EGFR. Dasatinib is a drug that can inhibit a group of proteins called SRC proteins. In addition, other experiments have suggested that other important signaling proteins are affected by dasatinib. Early phase trials of dasatinib are ongoing in cancer patients. It will be important to determine which patients receive a clinical benefit of dasatinib. Predetermination of treatment benefit can be performed by assessing biomarkers in patients tumors prior to treatment with dasatinib or other inhibitors of EGFR and SRC. Patients that have positive biomarkers for treatment could then be treated with higher confidence of benefit while those not possessing these predictive biomarkers would avoid ineffective and potentially toxic therapy. Additionally, treatment can be tailored according to predetermined sensitivity by evaluating indicated biomarkers correlating with sensitivity to one or more agents.

摘要翻译： 通过筛选关键生物标志物如EGFR的状态来预测EGFR和SRC抑制剂治疗反应的方法。 达沙替尼是一种可以抑制称为SRC蛋白质的蛋白质的药物。 此外，其他实验表明，其他重要的信号蛋白受dasatinib的影响。 达沙替尼的早期试验正在癌症患者中进行。 确定哪些患者获得达沙替尼的临床益处将是重要的。 可以通过在用达沙替尼或其他EGFR和SRC抑制剂治疗之前评估患者肿瘤中的生物标志物来进行治疗益处的预测。 那些具有阳性生物标志物治疗的患者然后可以以更高的信心获得治疗，而不具有这些预测性生物标志物的患者将避免无效和潜在的毒性治疗。 此外，可以通过评估与一种或多种试剂的敏感性相关的指示生物标志物，根据预定的灵敏度来定制治疗。